The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
The hormone decreases a type of white blood cell that helps keep tumors in check; restricting the hormone could be a ...
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...
Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors, but a new study by Duke Cancer ...
His book, “American Ramble,” lyrically recounted a 330-mile trek from Washington, D.C., to New York City while he was in ...
A recent report by the American Association for Cancer Research suggests adding cancer-specific warning labels to alcoholic ...
Even 1 drink a day can increase the risk of several cancers, including breast and colorectal cancers, according to a new ...
It’s probably the single worst thing you can do for yourself,” Dr. Jeremy London, a heart surgeon based in Savannah, said ...
Steve Langion was a firefighter, paramedic, ski patroller and a revered member of the Telluride community. He was always ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...
Drawing in the organs of individual breast cancer patients and then creating precise radiation plans appears to be faster by ...
The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered. | The days of broad stomach cancer labels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback